The use of methylphenidate for physical and psychological symptoms in cancer patients: A review

Beatrice Ng Andrew, Ng Chong Guan, Nik Ruzyanei Nik Jaafar

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: One of the goals of cancer treatment is symptoms management especially at the end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive dysfunction. The available treatment options for symptom management are limited. Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we review the use of methylphenidate for symptoms control in cancer patients. Method: Electronic literature search on PubMed was conducted using the following keywords: methylphenidate, cancer, carcinoma, oncology, oncological and tumour. We identified forty two relevant studies and publications on the use of methylphenidate in cancer patients to be included in this review. Results: Methylphenidate was found to have some evidence in reducing opioid-induced sedation, improving cognitive symptoms and reduction of fatigue in cancer patients. Nevertheless, the results were inconsistent due to variations in the study populations, study design and outcome measures, among others. There was minimal evidence on its use in treating depression. Otherwise, methylphenidate was generally well-tolerated by patients. Conclusion: This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients. Further placebo-controlled trials would help in strengthening the evidence for this treatment.

Original languageEnglish
Pages (from-to)877-887
Number of pages11
JournalCurrent Drug Targets
Volume19
Issue number8
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Methylphenidate
Psychology
Neoplasms
Fatigue
Oncology
Fatigue of materials
Opioid Analgesics
Depression
Neurobehavioral Manifestations
PubMed
Publications
Tumors
Therapeutics
Placebos
Outcome Assessment (Health Care)
Carcinoma
Population

Keywords

  • Cancer
  • Cognition
  • Depression
  • Fatigue
  • Methylphenidate
  • Pain

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

The use of methylphenidate for physical and psychological symptoms in cancer patients : A review. / Andrew, Beatrice Ng; Guan, Ng Chong; Nik Jaafar, Nik Ruzyanei.

In: Current Drug Targets, Vol. 19, No. 8, 01.01.2018, p. 877-887.

Research output: Contribution to journalReview article

@article{0c306fe6ea194e10aba99ba19c2e4473,
title = "The use of methylphenidate for physical and psychological symptoms in cancer patients: A review",
abstract = "Background: One of the goals of cancer treatment is symptoms management especially at the end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive dysfunction. The available treatment options for symptom management are limited. Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we review the use of methylphenidate for symptoms control in cancer patients. Method: Electronic literature search on PubMed was conducted using the following keywords: methylphenidate, cancer, carcinoma, oncology, oncological and tumour. We identified forty two relevant studies and publications on the use of methylphenidate in cancer patients to be included in this review. Results: Methylphenidate was found to have some evidence in reducing opioid-induced sedation, improving cognitive symptoms and reduction of fatigue in cancer patients. Nevertheless, the results were inconsistent due to variations in the study populations, study design and outcome measures, among others. There was minimal evidence on its use in treating depression. Otherwise, methylphenidate was generally well-tolerated by patients. Conclusion: This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients. Further placebo-controlled trials would help in strengthening the evidence for this treatment.",
keywords = "Cancer, Cognition, Depression, Fatigue, Methylphenidate, Pain",
author = "Andrew, {Beatrice Ng} and Guan, {Ng Chong} and {Nik Jaafar}, {Nik Ruzyanei}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1389450118666170317162603",
language = "English",
volume = "19",
pages = "877--887",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "8",

}

TY - JOUR

T1 - The use of methylphenidate for physical and psychological symptoms in cancer patients

T2 - A review

AU - Andrew, Beatrice Ng

AU - Guan, Ng Chong

AU - Nik Jaafar, Nik Ruzyanei

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: One of the goals of cancer treatment is symptoms management especially at the end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive dysfunction. The available treatment options for symptom management are limited. Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we review the use of methylphenidate for symptoms control in cancer patients. Method: Electronic literature search on PubMed was conducted using the following keywords: methylphenidate, cancer, carcinoma, oncology, oncological and tumour. We identified forty two relevant studies and publications on the use of methylphenidate in cancer patients to be included in this review. Results: Methylphenidate was found to have some evidence in reducing opioid-induced sedation, improving cognitive symptoms and reduction of fatigue in cancer patients. Nevertheless, the results were inconsistent due to variations in the study populations, study design and outcome measures, among others. There was minimal evidence on its use in treating depression. Otherwise, methylphenidate was generally well-tolerated by patients. Conclusion: This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients. Further placebo-controlled trials would help in strengthening the evidence for this treatment.

AB - Background: One of the goals of cancer treatment is symptoms management especially at the end stage. The common symptoms in cancer include pain, fatigue, depression and cognitive dysfunction. The available treatment options for symptom management are limited. Methylphenidate, a psychostimulant, may be of benefit for these patients. In this report, we review the use of methylphenidate for symptoms control in cancer patients. Method: Electronic literature search on PubMed was conducted using the following keywords: methylphenidate, cancer, carcinoma, oncology, oncological and tumour. We identified forty two relevant studies and publications on the use of methylphenidate in cancer patients to be included in this review. Results: Methylphenidate was found to have some evidence in reducing opioid-induced sedation, improving cognitive symptoms and reduction of fatigue in cancer patients. Nevertheless, the results were inconsistent due to variations in the study populations, study design and outcome measures, among others. There was minimal evidence on its use in treating depression. Otherwise, methylphenidate was generally well-tolerated by patients. Conclusion: This review potentially supports the use of methylphenidate for opioid-induced sedation, cognitive decline and fatigue in cancer patients. Further placebo-controlled trials would help in strengthening the evidence for this treatment.

KW - Cancer

KW - Cognition

KW - Depression

KW - Fatigue

KW - Methylphenidate

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=85048990795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048990795&partnerID=8YFLogxK

U2 - 10.2174/1389450118666170317162603

DO - 10.2174/1389450118666170317162603

M3 - Review article

C2 - 28322161

AN - SCOPUS:85048990795

VL - 19

SP - 877

EP - 887

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 8

ER -